Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  With the dedicated support, and particularly the experienced, constructive work of Bioscience Valuation, we accomplished meaningful results that provide important new knowledge enabling our next steps in diabetes research. We sincerely thank the entire Bioscience Valuation team for their valuable and straightforward collaboration in the past year, and look forward to the next opportunity of working with them again.

Prof. Dr. Thomas Danne, Director, and Dr. Bärbel Aschemeier, Clinical Research, AUF DER BULT Hospital for Children and Adolescents

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model


Bioscience Valuation's Valuation Model
Customers may license Bioscience Valuation's programs for their own use. Bioscience Valuation's Valuation Model provides unparalleled analysis capabilities that include, among others, the following key features:
  • intuitive use and interpretation of results,
  • sensitivity analyses for the most important input variables,
  • ability to determine the expected value increase as the project progresses during development,
  • guidance on discount rates,
  • easily used together with Bioscience Valuation's Market and R&D Risk models for comprehensive analysis.

Bioscience Valuation offers training courses for clients who license its valuation model.

Please contact us for receiving further information, or to order the model.